BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline

BioMarin announced a definitive agreement to acquire Alesta Therapeutics for $275 million upfront, plus up to $215 million in milestone payments, to secure ALE1, a Phase 1/2a oral therapy for hypophosphatasia (HPP). The acquisition is expected to close this quarter and will be funded using cash on hand, with Alesta spinning out non-ALE1 assets and no employees transferring to BioMarin.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.